Durvalumab (MEDI4736) and TREmelimumab in NEOadjuvant Bladder Cancer Patients (DUTRENEO)

NCT03472274 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

101

Enrollment

OTHER

Sponsor class

Conditions

Bladder Cancer

Interventions

DRUG: Durvalumab
DRUG: Tremelimumab
DRUG: Cisplatin-based neoadjuvant chemotherapy

Sponsor

Fundacion CRIS de Investigación para Vencer el Cáncer

Collaborators

[object Object]
[object Object]